U-Blot® Research Grade Anti-Human CLDN18.2 (M108)Cat. No. WA1828Request quote
Size: 50ug/100ug
Biosimilar antibodies are developed strictly against reference therapeutic mAbs. Validated through multi-dimensional physicochemical, functional and clinical studies, they exhibit highly consistent efficacy and safety profiles compared with originator products, featuring cost advantages and stable lot-to-lot quality.
U-Blot® Research Grade Anti-Human CLDN18.2 (M108)Cat. No. WA1828
U-Blot® Research Grade Anti-Human CLDN18.2 (LB1904)Cat. No. WA1827
U-Blot® Research Grade Anti-Human CLDN18.2 (GB7004-09)Cat. No. WA1826
U-Blot® Research Grade Anti-Human CLDN18.2 (DR30303)Cat. No. WA1825
U-Blot® Research Grade Anti-Human CLDN18.2 (CT041)Cat. No. WA1824
U-Blot® Research Grade Anti-Human CLDN18.2 (CMG910)Cat. No. WA1823
U-Blot® Research Grade Anti-Human CLDN18.2 (BNT141)Cat. No. WA1822
U-Blot® Research Grade Anti-Human CLDN18.2 (BC008)Cat. No. WA1821
U-Blot® Research Grade Anti-Human CLDN18.2 (ATG-022)Cat. No. WA1820
U-Blot® Research Grade Anti-Human CLDN18.2 (AB011)Cat. No. WA1819
U-Blot® Research Grade Anti-Human CLDN1 (ALE.F02)Cat. No. WA1818
U-Blot® Research Grade Anti-Human CFR-1/GLG1 (PAT-PA1)Cat. No. WA1817